01/30/2019
GCV Rising Stars Awards 2019: Jack Miner
Jack Miner leads Cleveland Clinic Ventures, a team of venture experts charged with funding the full lifecycle – from product-development company to exit – at the US-based healthcare services provider.
01/02/2019
Astellas Executes License Agreement with an Option to Acquire JVS-100 Gene Therapy Program from Juventas
Developed through research at Cleveland Clinic, Juventas Therapeutics, the clinical stage biotechnology company, is a pioneer in non-viral gene therapies. Licensed and spun-out through Cleveland Clinic Innovations, Juventas raised more than $50 million to advance its primary gene therapy candidate JVS-100, from concept through Phase II clinical studies in heart failure and Peripheral Artery Disease (PAD).
12/12/2018
Subscribe From Subaru Ascent to Apple Watch Series 4: The biggest product launches of 2018
This year, American consumer confidence hit a near 18-year high. These conditions – which often translate to increased consumer spending – provide an ideal environment for companies to introduce innovative new products. Prevent Biometrics is listed at #5.
10/22/2018
Prevent Biometrics® Acquires Assets of X2 Biosystems, Consolidating Leadership in Head Impact Monitoring
Prevent Biometrics, the Cleveland Clinic spinoff that developed the first accurate, real-time system for monitoring head impacts in contact sports, today announced that it has acquired the head impact monitoring assets of Seattle-based X2 Biosystems. The transaction brings together the two leading head impact monitoring technologies, Prevent’s Impact Monitor Mouthguard, and X2’s skin patch-based platform.
06/01/2018
Cleveland Clinic spinoff develops mouthguard that accesses concussion effects
The atmosphere inside the boxing gym was humid and reeked of sweat. Antonio Nieves, a former Cleveland Golden Gloves champion bantamweight, adjusted his digital mouthguard as he waited for his sparring match to start.
05/29/2018
ClearFlow Announces Additional Positive US Clinical Trial Results at the 2018 NTI Critical Care Exposition
ClearFlow, Inc., a medical device company based in Anaheim, California, has announced that positive clinical trial results were presented at the National Teaching Institute (NTI) & Critical Care Exposition 2018 annual meeting on May 23rd, 2018 in Boston, MA. The findings were presented by the study principal investigator, Dr. Yvon Baribeau, of Catholic Medical Center in Manchester, New Hampshire, in a presentation titled “Active Clearance of Chest Drains Reduces Pleural Effusions and ICU Resources in patients undergoing Cardiac Surgery.”
05/29/2018
Cleveland Clinic spinoff is at the center of efforts to remake the operating room
Centerline Biomedical, a Cleveland Clinic spinoff, is part of this Wall Street Journal story about tech advances that are making the operating room "smarter, more effective — and a lot less risky for patients."
05/29/2018
Merchavia Reports Positive Results in a Breakthrough Trial for Early Prostate Cancer Diagnosis
Merchavia Holdings and Investments (TASE: MRHL), an Israeli investment company specializing in early-stage life science sector companies, reports positive results from a successful trial which was conducted Cleveland Clinic, a leading medical center, using IsoPSA, a test developed by CDx (in which Merchavia holds about 8%).
05/21/2018
NaviGate Cardiac Structures Inc. (“NCSI”) reports “excellent valvular function” at 1-year follow-up of first patient to receive GATE™ tricuspid valved stent via transjugular access
NaviGate Cardiac Structures Inc. (“NCSI”) announced today that the first patient to receive its replacement tricuspid valved stent via transjugular access has reached one-year post-procedure with excellent valvular function.
05/19/2018
Assay May Help Avoid Needless Prostate Biopsies
An assay that identifies abnormal PSA proteins showed promise as an aid to avoid unnecessary prostate biopsies triggered by worrisome PSA test results, according to data reported here.